☰

Mark A. Agius - Publications

Affiliations: 
Neuroscience University of California, Davis, Davis, CA 
Area:
Neuroscience Biology, Immunology
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

37 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismyth R, Ashokkumar A, Bermel R, Ecklund D, Koepp M, Long J, ... ... Agius M, et al. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemporary Clinical Trials. PMID 27521810 DOI: 10.1016/J.Cct.2016.08.009  0.303
2016 Hunter SF, Agius M, Miller DM, Cutter G, Barbato L, McCague K, Meng X, Agashivala N, Chin P, Hollander E. Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial. Journal of the Neurological Sciences. 365: 190-8. PMID 27206905 DOI: 10.1016/J.Jns.2016.03.024  0.318
2014 Hughes B, Cascione M, Freedman MS, Agius M, Kantor D, Gudesblatt M, Goldstick LP, Agashivala N, Schofield L, McCague K, Hashmonay R, Barbato L. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders. 3: 620-8. PMID 26265274 DOI: 10.1016/J.Msard.2014.06.006  0.307
2014 Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Neurology. 13: 545-56. PMID 24685276 DOI: 10.1016/S1474-4422(14)70049-3  0.316
2014 Agius M, Meng X, Chin P, Grinspan A, Hashmonay R. Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom. Cns Neuroscience & Therapeutics. 20: 446-51. PMID 24684973 DOI: 10.1111/Cns.12235  0.324
2014 Berkovich R, Agius MA. Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis. Therapeutic Advances in Neurological Disorders. 7: 83-96. PMID 24587825 DOI: 10.1177/1756285613518599  0.348
2014 Morell SW, Trinh VB, Gudipati E, Friend A, Page NA, Agius MA, Richman DP, Fairclough RH. Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor. Molecular Immunology. 58: 116-31. PMID 24333757 DOI: 10.1016/J.Molimm.2013.11.005  0.312
2012 Richman DP, Nishi K, Ferns MJ, Schnier J, Pytel P, Maselli RA, Agius MA. Animal models of antimuscle-specific kinase myasthenia. Annals of the New York Academy of Sciences. 1274: 140-7. PMID 23252909 DOI: 10.1111/J.1749-6632.2012.06782.X  0.325
2012 Richman DP, Nishi K, Morell SW, Chang JM, Ferns MJ, Wollmann RL, Maselli RA, Schnier J, Agius MA. Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes. Archives of Neurology. 69: 453-60. PMID 22158720 DOI: 10.1001/Archneurol.2011.2200  0.359
2011 Apperson ML, Agius MA. Clinical and neuroimaging assessments for research studies (including drug trials) in multiple sclerosis. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit10.4. PMID 21207365 DOI: 10.1002/0471142301.Ns1004S54  0.317
2005 O'Connor P, Miller D, Riester K, Yang M, Panzara M, Dalton C, Miszkiel K, Khan O, Rice G, Sheremata W, Barker GJ, MacManus DG, Webb C, Middleditch C, Lewis S, ... ... Agius M, et al. Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis Multiple Sclerosis. 11: 568-572. PMID 16193895 DOI: 10.1191/1352458505Ms1205Oa  0.301
2004 Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology. 63: S8-14. PMID 15623672 DOI: 10.1212/Wnl.63.12_Suppl_6.S8  0.33
2004 Cohen BA, Khan O, Jeffery DR, Bashir K, Rizvi SA, Fox EJ, Agius M, Bashir R, Collins TE, Herndon R, Kinkel P, Mikol DD, Picone MA, Rivera V, Tornatore C, et al. Identifying and treating patients with suboptimal responses. Neurology. 63: S33-40. PMID 15623669 DOI: 10.1212/Wnl.63.12_Suppl_6.S33  0.338
2004 Wolinsky JS, Kastrukoff L, Duquette P, Freedman M, O'Connor P, Debouverie M, Lubetski C, Edan G, Roullet E, Confavreux C, Thompson A, Blumhardt L, Hawkins S, Scott T, Wynn D, ... ... Agius M, et al. The PROMiSe trial: baseline data review and progress report. Multiple Sclerosis Journal. 10. DOI: 10.1191/1352458504Ms1034Oa  0.323
2003 Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology. 61: 1652-61. PMID 14694025 DOI: 10.1212/01.Wnl.0000098887.24618.A0  0.368
2003 Richman DP, Agius MA. Treatment principles in the management of autoimmune myasthenia gravis. Annals of the New York Academy of Sciences. 998: 457-72. PMID 14592915 DOI: 10.1196/Annals.1254.060  0.379
2003 Agius MA, Richman DP, Fairclough RH, Aarli J, Gilhus NE, Romi F. Three forms of immune myasthenia. Annals of the New York Academy of Sciences. 998: 453-6. PMID 14592914 DOI: 10.1196/Annals.1254.059  0.382
2000 Agius MA. Treatment of ocular myasthenia with corticosteroids: Yes Archives of Neurology. 57: 750-751. PMID 10815145 DOI: 10.1001/Archneur.57.5.750  0.354
2000 Mygland A, Vincent A, Newsom-Davis J, Kaminski H, Zorzato F, Agius M, Gilhus NE, Aarli JA. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Archives of Neurology. 57: 527-31. PMID 10768628 DOI: 10.1001/Archneur.57.4.527  0.4
1999 Agius MA, Kirvan CA, Schafer AL, Gudipati E, Zhu S. High prevalence of anti-α-crystallin antibodies in multiple sclerosis: Correlation with severity and activity of disease Acta Neurologica Scandinavica. 100: 139-147. PMID 10478576 DOI: 10.1111/J.1600-0404.1999.Tb00729.X  0.368
1998 Lee EK, Maselli RA, Ellis WG, Agius MA. Morvan's fibrillary chorea: A paraneoplastic manifestation of thymoma Journal of Neurology Neurosurgery and Psychiatry. 65: 857-862. PMID 9854961 DOI: 10.1136/Jnnp.65.6.857  0.316
1998 Agius MA, Yuen E. Effect of anti-idiotopic antibody on the course of experimental autoimmune myasthenia gravis Annals of the New York Academy of Sciences. 841: 584-586. PMID 9668301 DOI: 10.1111/J.1749-6632.1998.Tb10989.X  0.375
1998 Agius MA, Zhu S, Fairclough RH. Antirapsyn antibodies in chronic procainamide-associated myopathy (CPAM) Annals of the New York Academy of Sciences. 841: 527-529. PMID 9668287 DOI: 10.1111/J.1749-6632.1998.Tb10975.X  0.332
1998 Agius MA, Zhu S, Aarli JA. Antirapsyn antibodies occur commonly in patients with lupus Annals of the New York Academy of Sciences. 841: 525-526. PMID 9668286 DOI: 10.1111/J.1749-6632.1998.Tb10974.X  0.387
1998 Agius MA, Zhu S, Kirvan CA, Schafer AL, Lin MY, Fairclough RH, Oger JJF, Aziz T, Aarli JA. Rapsyn antibodies in myasthenia gravis Annals of the New York Academy of Sciences. 841: 516-521. PMID 9668284 DOI: 10.1111/J.1749-6632.1998.Tb10972.X  0.366
1998 Agius MA, Kirvan CA, Sanyal B. Homology of an antiacetylcholine receptor monoclonal antibody with a monoclonal antibody to Campath-1 antigen suggests usage of the same V(H) genes Annals of the New York Academy of Sciences. 841: 469-470. PMID 9668276 DOI: 10.1111/J.1749-6632.1998.Tb10964.X  0.355
1998 Kirvan CA, Zhu S, Richman DP, Agius MA. Expression and initial characterization of recombinant antiacetylcholine receptor antibodies in experimental autoimmune myasthenia gravis Annals of the New York Academy of Sciences. 841: 466-468. PMID 9668275 DOI: 10.1111/J.1749-6632.1998.Tb10963.X  0.36
1998 Richman DP, Agius MA, Kirvan CA, Gomez CM, Fairclough RH, Dupont BL, Maselli RA. Antibody effector mechanisms in myasthenia gravis. The complement hypothesis. Annals of the New York Academy of Sciences. 841: 450-65. PMID 9668274 DOI: 10.1111/J.1749-6632.1998.Tb10962.X  0.362
1998 Agius MA, Twaddle GM, Fairclough RH. Epitope spreading in experimental autoimmune myasthenia gravis Annals of the New York Academy of Sciences. 841: 365-367. PMID 9668260 DOI: 10.1111/J.1749-6632.1998.Tb10948.X  0.316
1998 Agius MA, Fairclough RH. Novel autoimmune targets and crossreactivity in myasthenia gravis Clinical Immunology Newsletter. 18: 16-19. DOI: 10.1016/S0197-1859(00)89167-0  0.375
1997 Agius MA, Chan JW, Chung S, Lee EK. Role of antiribosomal P protein antibodies in the diagnosis of lupus isolated to the central nervous system Archives of Neurology. 54: 862-864. PMID 9236575 DOI: 10.1001/Archneur.1997.00550190052014  0.371
1994 Richman DP, Agius MA. Acquired myasthenia gravis: Immunopathology Neurologic Clinics. 12: 273-284. PMID 8041342 DOI: 10.1016/S0733-8619(18)30097-5  0.389
1993 Agius MA, Sanyal B, Richman DP. Molecular structure of a monoclonal antiacetylcholine receptor antibody and of a corresponding monoclonal antiidiotopic antibody Annals of the New York Academy of Sciences. 681: 274-275. PMID 8357167 DOI: 10.1111/J.1749-6632.1993.Tb22892.X  0.36
1993 Richman DP, Wollmann RL, Maselli RA, Gomez CM, Corey AL, Agius MA, Fairclough RH. Effector mechanisms of myasthenic antibodies. Annals of the New York Academy of Sciences. 681: 264-73. PMID 8357166 DOI: 10.1111/J.1749-6632.1993.Tb22891.X  0.353
1987 Blair DA, Mihovilovic M, Agius MA, Fairclough RH, Richman DP. Human x human hybridomas from patients with myasthenia gravis: possible tools for idiotypic therapy for myasthenia. Annals of the New York Academy of Sciences. 505: 155-67. PMID 3500665 DOI: 10.1111/J.1749-6632.1987.Tb51289.X  0.378
1987 Agius MA, Richman DP. Antiidiotopic modification of the anti-acetylcholine receptor immune response and of experimental autoimmune myasthenia gravis in Lewis rats Annals of the New York Academy of Sciences. 505: 896-897. DOI: 10.1111/J.1749-6632.1987.Tb51405.X  0.304
1987 Yuen EC, Agius MA, Corey AL, Richman DP. Modification of experimental autoimmune myasthenia gravis with anti-idiotopic antibody administered after immunization with antigen Journal of Neuroimmunology. 16: 191-192. DOI: 10.1016/0165-5728(87)90429-2  0.376
Show low-probability matches.